Rein Therapeutics (RNTX) Shares Outstanding (2016 - 2026)
Rein Therapeutics (RNTX) posted quarterly Shares Outstanding (Entity) of $28.0 million for Q1 2026, up 27.42% year-over-year from $22.0 million in Q1 2025, and up 1.77% quarter-over-quarter from $27.6 million in Q4 2025.
Rein Therapeutics (RNTX) Shares Outstanding (2016 - 2026) Analysis & Trends
Rein Therapeutics (RNTX) has reported Shares Outstanding (Entity) for 11 consecutive years, with $28.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 27.42% year-over-year to $28.0 million; the TTM figure through Mar 2026 stood at $28.0 million (up 27.42% YoY), while the FY2025 annual figure was $27.6 million, up 53.58% from the prior year.
- Shares Outstanding (Entity) rose to $28.0 million in Q1 2026 per RNTX's latest filing, from $27.6 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $28.0 million in Q1 2026 and bottomed at $4.5 million in Q4 2022.
- Historically, Shares Outstanding (Entity) has averaged $13.6 million across 5 years, with a median of $8.3 million in 2024.
- Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) dropped 0.0% — and 2024, when it soared 377.1%.
- Rein Therapeutics' Shares Outstanding (Entity) stood at $4.5 million in 2022, then climbed by 7.58% to $4.9 million in 2023, then surged by 267.19% to $17.9 million in 2024, then jumped by 53.58% to $27.6 million in 2025, then rose by 1.77% to $28.0 million in 2026.
- Business Quant data shows RNTX's Shares Outstanding (Entity) at $28.0 million in Q1 2026, $27.6 million in Q4 2025, and $25.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Rein Therapeutics | 55.49 Mn | 55.49 Mn | - | 67.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 67.08 Mn |
| Mar 31, 2026 | 30.35 Mn |
| Dec 31, 2025 | 25.44 Mn |
| Sep 30, 2025 | 26.36 Mn |
| Jun 30, 2025 | 24.19 Mn |
| Mar 31, 2025 | 21.92 Mn |
| Dec 31, 2024 | 17.94 Mn |
| Sep 30, 2024 | 21.66 Mn |
| Jun 30, 2024 | 19.91 Mn |
| Mar 31, 2024 | 8.30 Mn |
| Dec 31, 2023 | 4.60 Mn |
| Sep 30, 2023 | 4.54 Mn |
| Jun 30, 2023 | 4.54 Mn |
| Mar 31, 2023 | 4.54 Mn |
| Dec 31, 2022 | 4.54 Mn |
| Sep 30, 2022 | 4.54 Mn |
| Jun 30, 2022 | 4.54 Mn |
| Mar 31, 2022 | 4.53 Mn |
| Dec 31, 2021 | 4.44 Mn |
| Sep 30, 2021 | 4.53 Mn |